Understanding ONTOZRY^®▼ (cenobamate)

Epilepsy is characterised by abnormal electrical activity in the brain that can cause seizures, unusual behaviour or sensations, and sometimes loss of awareness.¹

These include genetic defects, stroke, head injury, infection or immune disorders. The cause of epilepsy may not be identifiable (“unknown cause”).^{3, 4}

The first step in classifying epilepsy is by looking at the area of onset – where the seizure starts in the brain.⁵

There are three broad types: ^{5, 6}

Focal onset: Seizures start in one area of the brain.

Generalised onset: Seizures affect both sides of the brain at the same time.

Unknown onset: Seizures where the area of onset is not known.

If you are not a patient or a carer of a patient who has been prescribed ONTOZRY^® and you would like to find out more about Angelini, please click here.

Your doctor has prescribed ONTOZRY^® in addition to your current epilepsy treatments, to help you manage your condition. Taking ONTOZRY^® regularly can help you manage your focal-onset seizures.

If you need advice or have any questions about your epilepsy or the treatment you have been prescribed, please speak to a healthcare professional.

1. What ONTOZRY^® is and what it is used for.
2. What you need to know before you take ONTOZRY^®.
3. How to take ONTOZRY^®.
4. Possible side effects.
5. How to store ONTOZRY^®.
6. Contacts of the pack and other information.

Download and print the patient information leaflet Click Here.

Visit the ONTOZRY^® Summary of Product Characteristics (SmPC) Click Here.

Visit the ONTOZRY^® Public Assessment Report (PAR) Click Here.

ONTOZRY^® contains the active substance cenobamate. It belongs to a group of medicines called ‘anti-epileptics’. These medicines are used to treat epilepsy, a condition where someone has seizures or fits because of abnormal activity in the brain.

ONTOZRY^® is used in combination with other anti-epileptic medicines in adult patients with epilepsy who have not been adequately controlled despite treatment with at least 2 anti-epileptic products, to treat a type of epilepsy that has focal-onset seizures, with or without secondary generalisation. Focal-onset seizures are those caused by abnormal brain activity starting in a part of the brain on one side, and secondary generalisation means that the abnormal activity is spreading to both sides of the brain. The medicine can be used only in adults.

• You are allergic to cenobamate or any of the other ingredients of this medicine.
• You were born with heart problems, with changes in the electrical activity of the heart, related to a rare condition called familial short-QT syndrome.

Talk to your doctor or pharmacist before taking ONTOZRY^® or during treatment if:

• You have thoughts of harming or killing yourself. A few people being treated with anti-epileptic medicines such as ONTOZRY^® have had thoughts of harming or killing themselves. If you have any of these thoughts at any time, contact your doctor immediately.
• You have a serious skin reaction which may include high temperature and other flu-like symptoms, rash on the face, rash spreading to other parts of the body, swollen glands (enlarged lymph nodes); and blood tests showing increased levels of liver enzymes and of a type of white blood cell (eosinophilia).

ONTOZRY^® is not recommended in children and adolescents under 18 years, as it was not investigated in this group.

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

Taking ONTOZRY^® with certain other medicines may affect how the other medicines work or how ONTOZRY^® works. Do not start or stop other medicines without talking to your doctor or pharmacist.

Tell your doctor if you are taking any of the following medicines, as your dose may need to be adjusted:

• Medicines used to help you fall asleep such as barbiturates and benzodiazepines.
• Other medicines to treat epilepsy, such as clobazam, phenytoin, phenobarbital and lamotrigine.
• Birth control medicines (oral contraceptives) as these may be less effective when combined with ONTOZRY^®. Your doctor may prescribe alternative methods for preventing pregnancy while you take this medicine and up to 4 weeks after you stop taking this medicine. Patients are encouraged to use barrier contraception whilst taking ONTOZRY^®.
• Medicines, which are known to be transformed in the body by specific groups of enzymes such as midazolam (a medicine used to stop prolonged, acute [sudden] convulsive seizures, for sedation and sleep problems), bupropion (a medicine used to help stop smoking), omeprazole (a medicine used to treat heartburn or stomach ulcer), baricitinib (a medicine used to treat painful inflammation of the joints or skin eczema), cefaclor (an antibiotic), empagliflozin (a medicine used to treat high blood glucose in diabetes), Penicillin G (an antibiotic), ritobegron (a medicine used to treat overactive bladder), sitagliptin (a medicine used to control high blood glucose in diabetes).

Do not take this medicine with alcohol. ONTOZRY^® can increase the effects of alcohol such as feeling tired or sleepy and you should not drink alcohol with this medicine.

If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before you take this medicine.

Only take ONTOZRY^® during pregnancy if you and your doctor decide that it is absolutely necessary. You must use effective contraception during use of ONTOZRY^® and until 4 weeks after you stop taking this medicine. Ask your doctor for advice regarding effective measures of birth control. You should stop breast-feeding while taking ONTOZRY^®.

• You may feel sleepy, dizzy or tired, and your vision may be reduced while taking ONTOZRY^®.
• These effects are more likely at the start of the treatment or after your dose is increased.
• Do not drive, cycle or use any tools or machines if your reactions are slowed down and until you know how the medicine affects you.

If you have been told by your doctor that you have an intolerance to some sugars, speak with your doctor before taking this medicine.

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

You will take ONTOZRY^® with other medicines to treat epilepsy.

You will start ONTOZRY^® with a daily dose of one 12.5 mg tablet for the first 2 weeks, followed by one 25 mg tablet once a day for the next 2 weeks. Then your dose will be gradually adjusted every 2 weeks until you reach the dose that works best for you. Your doctor will work out the right daily dose for you and may need to adjust it over time.

The recommended daily dose is between 200 mg and 400 mg once daily.

Take the recommended dose once a day at around the same time. You can take ONTOZRY^® at any time either during the day or in the evening, with food or between meals.

Swallow the tablets whole with a glass of water. Do not break the tablets in half because the tablets are not suitable for splitting into two equal halves.

Talk to your doctor; you may feel dizzy, tired and sleepy.

Take the forgotten dose as soon as you remember, if fewer than 12 hours have passed since you should have taken it. If more than 12 hours have passed, skip the forgotten dose and take the next dose at your regular time. Do not take a double dose to make up for a forgotten dose.

Do not reduce the dose or stop taking ONTOZRY^® without checking with your doctor. Your doctor will explain how to stop taking ONTOZRY^® by reducing the dose gradually.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Tell your doctor immediately if you have any of the following serious side effects:

• A serious skin reaction which may include fever and other flu-like symptoms, a rash on the face, rash spreading to other areas of the body, and swollen glands (enlarged lymph nodes). Blood tests may show increased levels of liver enzymes and of a type of white blood cell (eosinophilia).

• Feeling sleepy (somnolence), sedated or very tired (fatigue).
• Double vision (diplopia).
• Spinning sensation (vertigo).
• Having problems with coordination of movements, having problems walking or keeping your balance (ataxia, gait disturbance, abnormal coordination).
• Headache.

• Reduced memory, confusion.
• Excitability.
• Having difficulty in saying words or difficulty speaking.
• Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision, double vision.
• Nausea (feeling sick), vomiting, constipation or diarrhoea.
• Dry mouth.
• Rash, itching.
• Swollen eyelids, swollen limbs.
• Blood tests showing increases in levels of certain liver enzymes.

• Allergic reactions.

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system (see bottom of page). By reporting side effects you can help provide more information on the safety of this medicine.

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The expiry date refers to the last day of that month.

This medicine does not require any special storage conditions.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

The active substance is cenobamate.

• One ONTOZRY^® 12.5 mg film-coated tablet contains 12.5 mg cenobamate.
• One ONTOZRY^® 25 mg film-coated tablet contains 25 mg cenobamate.
• One ONTOZRY^® 50 mg film-coated tablet contains 50 mg cenobamate.
• One ONTOZRY^® 100 mg film-coated tablet contains 100 mg cenobamate.
• One ONTOZRY^® 150 mg film-coated tablet contains 150 mg cenobamate.
• One ONTOZRY^® 200 mg film-coated tablet contains 200 mg cenobamate.

The other ingredients are microcrystalline cellulose (E460), lactose monohydrate, sodium starch glycolate, silica colloidal anhydrous (E551), magnesium stearate (E470b).

• 25 mg and 100 mg film-coated tablets: indigo carmine aluminium lake (E132), iron oxide red (E172), iron oxide yellow (E172), macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171).
• 50 mg film-coated tablets: iron oxide yellow (E172), macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc, titanium dioxide (171).
• 50 mg and 200 mg film-coated tablets: iron oxide red (E172), iron oxide yellow (E172), macrogol, partially hydrolysed poly(vinyl alcohol) (E1203), talc (E553b), titanium dioxide (E171).

• ONTOZRY^® 12.5 mg are uncoated round white to off-white tablets with AV on one side and ‘12’ on the other side.
• ONTOZRY^® 25 mg are round brown film-coated tablets with AV on one side and ‘25’ on the other side.
• ONTOZRY^® 50 mg are round yellow film-coated tablets with AV on one side and ‘50’ on the other side.
• ONTOZRY^® 100 mg are round brown film-coated tablets with AV on one side and ‘100’ on the other side.
• ONTOZRY^® 150 mg are round light orange film-coated tablets with AV on one side and ‘150’ on the other side.
• ONTOZRY^® 200 mg are oval light orange film-coated tablets with AV on one side and ‘200’ on the other side.
• ONTOZRY^® Treatment Initiation pack contains 14 tablets of 12.5 mg and 14 film-coated tablets of 25 mg.
• ONTOZRY^® 50 mg, 100 mg, 150 mg and 200 mg film-coated tablets are available in packs of 14, 28 or 84.

Please note, not all pack sizes may be available.

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card System at www.MHRA.gov.uk/yellowcard for the UK or www.hpra.ie for Ireland. By reporting side effects you can help provide more information on the safety of this medicine.

UK456NP | November 2022